Table 5.
Trials with immune checkpoint inhibitors (ICIs) during or after concurrent chemoradiation (CRT) in stage III lung cancers
| Author Trial Title | Antonia(22) PACIFIC | Antonia(22) PACIFIC | Durm(47) HCRN | Peters(48) ETOP NICHOLAS | Lin(49) DETERRED |
|---|---|---|---|---|---|
| Agent | Durvalumab | Placebo | Pembrolizumab | Nivolumab | Atezolizumab |
| Patients | 473 | 236 | 93 | 80 | 40 |
| Timing of ICI | After CRT | - - - | After CRT | During CRT | During CRT |
| 18 Month Progression Free Survival |
44% |
27% |
50% |
Not Reported | Not Reported |
| Any Pneumonitis | 34% | 25% | Not Reported | 43% | 25% |
| ≥Gr 3 Pneumonitis | 3% | 3% | 6% | 10% | 3% |
| Deaths on Study | 4% | 6% | 3% | 9% | 5% |